{"pmid":32127666,"title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","text":["Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","Nat Rev Drug Discov","Li, Guangdi","De Clercq, Erik","32127666"],"journal":"Nat Rev Drug Discov","authors":["Li, Guangdi","De Clercq, Erik"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32127666","week":"202010|Mar 02 - Mar 08","doi":"10.1038/d41573-020-00016-0","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1661359647660965888,"score":6.7365713,"similar":[{"pmid":32104907,"title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.","text":["A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.","In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.","J Med Virol","Yao, Tian-Tian","Qian, Jian-Dan","Zhu, Wen-Yan","Wang, Yan","Wang, Gui-Qiang","32104907"],"abstract":["In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19."],"journal":"J Med Virol","authors":["Yao, Tian-Tian","Qian, Jian-Dan","Zhu, Wen-Yan","Wang, Yan","Wang, Gui-Qiang"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32104907","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25729","keywords":["COVID-19","MERS","SARS","coronavirus","lopinavir"],"source":"PubMed","locations":["vivo","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1661359647544573952,"score":40.936726}]}